NCT06712771View on ClinicalTrials.gov

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

45

Participants

Timeline

Start Date

December 2, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 30, 2027

Conditions

Homozygous Familial Hypercholesterolemia (HoFH)

Interventions

DRUG

VSA003

subcutaneous injections

DRUG

Placebo

subcutaneous injections

All Listed Sponsors

lead

Visirna Therapeutics HK Limited

INDUSTRY